Patents by Inventor Andrea Carfi

Andrea Carfi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VARIANT STRAIN-BASED CORONAVIRUS VACCINES
    Publication number: 20240139309
    Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 2, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamiltion Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
  • VARIANT STRAIN-BASED CORONAVIRUS VACCINES
    Publication number: 20240100151
    Abstract: The disclosure provides coronavirus mRNA vaccines, including vaccines directed against one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 28, 2024
    Applicant: Moderna TX, Inc.
    Inventors: Andrea Carfi, Guillaume Stewart-Jones, Hamilton Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
  • Modified cytomegalovirus proteins and stabilized complexes
    Patent number: 11932669
    Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: March 19, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Enrico Malito, Matthew James Bottomley, Andrea Carfi, Sumana Chandramouli, Kate Luisi
  • SARS-COV-2 MRNA DOMAIN VACCINES
    Publication number: 20230346914
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.
    Type: Application
    Filed: February 6, 2021
    Publication date: November 2, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Guillaume Stewart-Jones, Andrea Carfi, Sayda Mahgoub Elbashir, Mihir Metkar
  • PRE-FUSION RSV F ANTIGENS
    Publication number: 20230287056
    Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
    Type: Application
    Filed: April 27, 2023
    Publication date: September 14, 2023
    Inventors: Kurt SWANSON, Andrea CARFI
  • MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
    Publication number: 20230248820
    Abstract: Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 10, 2023
    Inventors: Enrico Malito, Sumana Chandramouli, Andrea Carfi, Matthew Bottomley
  • CORONAVIRUS RNA VACCINES
    Publication number: 20230108894
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 6, 2023
    Applicant: Moderna TX, Inc
    Inventors: Guillaume Stewart-Jones, Elisabeth Narayanan, Hamilton Bennett, Andrea Carfi, Mihir Metkar, Vladimir Presnyak
  • HUMAN CYTOMEGALOVIRUS VACCINE
    Publication number: 20220401551
    Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
    Type: Application
    Filed: June 14, 2022
    Publication date: December 22, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
  • PRE-FUSION RSV F ANTIGENS
    Publication number: 20220332767
    Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 20, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt SWANSON, Andrea CARFI
  • PRE-FUSION RSV F ANTIGENS
    Publication number: 20220332766
    Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 20, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt SWANSON, Andrea CARFI
  • Human cytomegalovirus vaccine
    Patent number: 11406703
    Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: August 9, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
  • COMPLEXES OF CYTOMEGALOVIRUS PROTEINS
    Publication number: 20220106364
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 7, 2022
    Inventors: Andrea CARFI, Yingxia WEN
  • HUMAN CYTOMEGALOVIRUS VACCINE
    Publication number: 20220062408
    Abstract: Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
    Type: Application
    Filed: August 25, 2021
    Publication date: March 3, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
  • MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
    Publication number: 20210277067
    Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 9, 2021
    Inventors: Enrico MALITO, Matthew James BOTTOMLEY, Andrea CARFI, Sumana CHANDRAMOULI, Kate LUISI
  • PRE-FUSION RSV F ANTIGENS
    Publication number: 20210269489
    Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
    Type: Application
    Filed: May 7, 2021
    Publication date: September 2, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Kurt SWANSON, Andrea CARFI
  • Mammalian cells expressing cytomegalovirus antigens
    Patent number: 10414802
    Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 17, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Claudio Ciferri, Irmgard Hofmann, Holger Laux, Anders Lilja, Yingxia Wen
  • CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF
    Publication number: 20190276498
    Abstract: The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.
    Type: Application
    Filed: November 15, 2018
    Publication date: September 12, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Andrea CARFI, Claudio CIFERRI, Yi XING
  • Cytomegalovirus antigens
    Patent number: 10364273
    Abstract: The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: July 30, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Sumana Chandramouli, Ethan C. Settembre
  • COMPLEXES OF CYTOMEGALOVIRUS PROTEINS
    Publication number: 20190211064
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 11, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea CARFI, Yingxia WEN
  • Complexes of cytomegalovirus proteins
    Patent number: 10287322
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Yingxia Wen